Skip to content

    Fortis Healthcare Q1 FY27 earnings call

    FORTIS
    Healthcare·7 Aug 2026
    Management Summary

    Fortis Healthcare reported a steady Q1 FY27 performance with consolidated revenue growing 17.5% to INR 2,545 crores. The hospital business saw a 19% revenue increase and improved ARPOB, while the diagnostics segment grew 10.2% with margin expansion. Despite a slight consolidated EBITDA margin dip (pre-ESOP) and slower oncology growth due to pricing pressures, the company is focused on strategic bed expansion, network growth, and operational efficiencies, targeting a 25% EBITDA margin by FY28.

    Highlights

    5

    • Consolidated revenue grew 17.5% YoY to INR 2,545 crores, demonstrating strong top-line performance.

    • Diagnostic business EBITDA margin improved to 23.9% from 23.0% in Q1 FY26, driven by productivity and richer test mix.

    • Occupied beds in hospitals increased by 17% to 3,418, and ARPOB grew 2.6% to INR 2.71 crores per annum.

    • The company added approximately 100 operational beds and entered into an O&M agreement for a 300-bedded hospital in Cuttack, expanding its presence.

    • B2C:B2B revenue mix in diagnostics improved to 53:47 from 51:49, and specialized portfolio contribution increased to 35%, indicating a favorable portfolio shift.

    Concerns

    4

    • Consolidated operating EBITDA margin slightly declined to 22.3% from 22.6% in Q1 FY26 (though similar at 22% excluding acquisitions), partly due to new facility ramp-ups and legal costs.

    • Net debt to EBITDA ratio increased to 1.01x from 0.92x in Q1 FY26, primarily due to acquisitions made last year.

    • Oncology business growth slowed significantly to 5% from 23-24% previously, impacted by the chemo drug pricing mechanism (30% discount on MRP).

    • Diagnostics business growth of 9-10% is slower than the industry average of 15%, despite internal improvements.

    Key financials

    Single quarter

    06 metrics
    1. 01Consolidated Revenue₹2,545 Cr+17.5%YoY
    2. 02Consolidated Operating EBITDA (pre-ESOP)₹568 Cr
    3. 03Consolidated Operating EBITDA Margin (pre-ESOP)22.3%
    4. 04Consolidated PAT (pre-exceptional)₹263 Cr+4%YoY
    5. 05Net Debt₹2,233 Cr

    Segment breakdown

    • Hospital Business₹471 Cr82.9%
    • Diagnostics Business (Agilus)₹97 Cr17.1%
    Donut· Share of Operating EBITDA

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹2,233 crores · 1.0x EBITDA

    M&A

    Acquisitions (Punjab, Bengaluru, Delhi NCR leased facility)

    acquisition · integrated

    M&A

    300-bedded greenfield multi-specialty hospital in Cuttack

    joint venture · announced

    Guidance & targets

    9
    CategoryTargetPriority
    Margin
    Consolidated EBITDA Margin
    25%
    		High
    Margin
    Manesar & Noida Hospital EBITDA Margin
    mid-teens or higher
    		Medium
    Margin
    Diagnostics EBITDA Margin
    24-25%
    		Medium
    Revenue Growth
    Diagnostics Revenue Growth
    12-13%
    		Medium
    Mix
    Diagnostics B2C Ratio
    55-58%
    		Medium
    Growth
    Oncology Business Growth
    10-12%
    		Medium
    Capacity
    Bed Expansion
    400 beds
    		High
    Cost
    ESOP Charge
    INR 40 crore per quarter (initially), then INR 30 crore, then INR 25 crore
    		High
    Occupancy
    Occupancy Improvement
    2-3 percentage points
    		Medium

    What to watch in Q2 FY27

    5

    Manesar & Noida Hospital EBITDA Margins

    by year-end
    CurrentBelow 10%
    TargetMid-teens or higher

    Why it matters

    Improvement in these new facilities is crucial for overall hospital segment profitability and achieving consolidated margin targets.

    Both these hospitals, by the year-end, certainly be in the mid-teens as far as EBITDA is concerned, if not higher.

    Risks & concerns

    6
    RiskSeverity

    Increased Net Debt due to Acquisitions

    Net debt to EBITDA ratio increased to 1.01x from 0.92x in Q1 FY26, primarily due to acquisitions made last year. — Management acknowledged

    medium

    Initial Impact of ESOP Charge on Profitability

    The ESOP charge will initially be higher (INR 40 crore per quarter) before gradually reducing, impacting reported profitability, though factored into long-term margin guidance. — Management acknowledged

    medium

    Slowdown in Oncology Business Growth

    Oncology growth declined to 5% from 23-24% due to the chemo drug pricing mechanism (30% discount on MRP) affecting government beneficiaries. — Management acknowledged

    medium

    Diagnostics Growth Below Industry Average

    Diagnostics business grew 9-10% compared to an industry average of 15%, indicating a need for accelerated growth. — Management acknowledged

    medium

    Impact of New Facility Ramp-ups on Margins

    New units like Manesar and Noida are currently operating at lower margins and contributed negatively by 0.4% to overall EBITDA margin in Q1 FY27. — Management acknowledged

    low

    Legal Costs and Doubtful Debt Provisions

    Legal costs related to Delhi High Court hearings and increased provision for doubtful debt due to collection delays impacted Q1 profitability. — Management acknowledged

    low

    Q&A highlights

    8

    “The strategy and the philosophy of ESOP was the work of primary consideration and there was a lot of deliberation and we decided that ESOP should be not only a tool to sort of recognize people's contribution, but at the same time, also be as a tool of how the organization functions in the future and how it performs in the future.”

    Clarifies the strategic rationale behind the ESOP scheme, emphasizing long-term alignment and performance improvement rather than just a reactive measure against poaching.

    asked by Tausif (BNP Paribas)

    3 min read6 chapters

    Detailed Narrative

    01

    Q1 FY27 Financial Performance Overview

    Fortis Healthcare reported a consolidated revenue of INR 2,545 crores for Q1 FY27, marking a 17.5% year-on-year growth. The hospital business contributed INR 2,187 crores, growing by 19%, while the diagnostics segment generated INR 407 crores, a 10.2% increase. Consolidated operating EBITDA pre-ESOP expenses stood at INR 568 crores, with a margin of 22.3%, a slight decrease from 22.6% in Q1 FY26. Consolidated PAT before exceptional items📎 increased by approximately 4% to INR 263 crores.

    02

    Hospital Business Operational Metrics and Expansion

    The hospital business maintained a steady occupancy rate of 69% in Q1 FY27, with the number of occupied beds increasing by 17% to 3,418 compared to the prior year. The average revenue per occupied bed (ARPOB) grew by 2.6%, reaching INR 2.71 crores per annum. Fortis operationalized approximately 100 new beds through brownfield expansion and plans to add another 400 beds in the remaining three quarters, with a significant contribution expected from FMRI. The company also entered Odisha via an O&M agreement for a 300-bedded multi-specialty hospital in Cuttack.

    03

    Diagnostics Segment Performance and Strategic Focus

    Agilus Diagnostics reported gross revenue of INR 407 crores, reflecting a 10.2% year-on-year growth, and an operating EBITDA of INR 97 crores, with its margin improving to 23.9% from 23.0% in Q1 FY26. The segment processed approximately 10.5 million tests and expanded its network by over 200 customer touch points. The B2C:B2B revenue mix improved to 53:47, and the contribution from preventive and specialized portfolios increased to 14% and 35% respectively, indicating a favorable shift in test mix. Management targets 12-13% revenue growth and 24-25% EBITDA margin for the diagnostics business.

    04

    Oncology Business Challenges and Mitigation Strategy

    The oncology business experienced a significant slowdown, with growth declining to 5% from a previous range of 23-24%. This was primarily attributed to the chemo drug pricing mechanism, which imposes a 30% discount on the MRP for beneficiaries of government schemes like ECHS and CGHS. To counter this, Fortis plans to drive future growth by focusing on radiation, surgical oncology, and providing comprehensive care, aiming to restore growth to 10-12%.

    05

    Capital Allocation and Debt Profile

    As of June 30, 2026, the company's net debt stood at INR 2,233 crores, leading to a net debt-to-EBITDA ratio of 1.01x, an increase from 0.92x in the prior year, mainly due to acquisitions. For brownfield expansion, Fortis plans to consume approximately 50% of its EBITDA to add 2,000 beds. The Board has also approved a Capex of INR 252 crores for the installation of a proton therapy facility at its flagship hospital in Gurgaon.

    06

    ESOP Scheme and Long-Term Margin Outlook

    Fortis implemented a broad-based ESOP scheme across its network, designed to align the interests of doctors and staff with the company's growth. The ESOP charge is expected to be INR 40 crore per quarter initially, gradually decreasing over three years. Despite this, management reiterated its confidence in achieving a 25% consolidated EBITDA margin by FY28, citing operational efficiencies, ramp-up of new facilities, and cost reductions as key drivers.

    This is an AI-generated summary of a publicly available earnings call transcript.